COMMUNIQUÉS West-GlobeNewswire

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
30/08/2024
Please see enclosed pdf. Attachment 30082024_trading_in_shares_PRM
Total number of shares and voting rights in Zealand Pharma on August 30, 2024
30/08/2024
Company announcement – No. 42 / 2024 Total number of shares and voting rights in Zealand Pharma on August 30, 2024 Copenhagen, Denmark, August 30, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 [...]
BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension
30/08/2024
- In participants who switched from tafamidis and placebo in the ATTRibute-CM study to acoramidis in its open-label extension (OLE), there was a mean of 3.0mg/dL increase in serum transthyretin (TTR) at Month 1 of the [...]
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
30/08/2024
Please see enclosed pdf. Attachment 30082024_trading_in_shares_ARA
Children’s Hospital at London Health Sciences Centre and Shriners Hospitals for Children Canada announce groundbreaking affiliation agreement
30/08/2024
In a Canadian first, the two major paediatric hospitals join forces to offer orthopaedic care closer to home and develop innovative teaching and research initiatives LONDON, Ontario, Aug. 30, 2024 (GLOBE NEWSWIRE) -- [...]
L’Hôpital pour enfants du Centre des sciences de la santé de London et les Hôpitaux Shriners pour enfants Canada annoncent une importante entente d'affiliation
30/08/2024
Une première en son genre au Canada, deux principaux hôpitaux pédiatriques unissent leurs forces pour offrir aux patients des soins orthopédiques spécialisé plus près du domicile et développer des initiatives innovantes [...]
Nymox Announces Filing of Annual Report
30/08/2024
IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) is pleased to report that it filed its Annual Report with the Security and Exchange Commission (SEC) on [...]
Scilex Holding Company to Present Oral, Poster Presentations and Symposia on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek Conference in Las Vegas, NV on September 3-5, 2024
30/08/2024
PALO ALTO, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non- [...]
SS Innovations Issues Update on Status of Audit Process and Trading Market for Common Stock
30/08/2024
FORT LAUDERDALE, Fla., Aug. 30, 2024 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), developer of innovative surgical robotic technologies dedicated to making [...]
Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness
30/08/2024
For the second year, Emergent is teaming up with pro football legend, Emmitt Smith, to educate communities on opioid risks and how to be prepared with NARCAN ® Nasal Spray In recognition of International Overdose [...]
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
30/08/2024
IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing [...]
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September
30/08/2024
NAARDEN, The Netherlands and MIAMI, Aug. 30, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]
Disc Medicine to Participate in Upcoming Investor Conferences
30/08/2024
WATERTOWN, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for [...]
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30/08/2024
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on August 26, 2024, the Compensation Committee of the Board of Directors [...]
Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference
30/08/2024
STOUGHTON, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious [...]
Ventyx Biosciences Announces Departure of Chief Financial Officer
30/08/2024
SAN DIEGO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of [...]
HOOKIPA Pharma Announces Board of Directors Changes
30/08/2024
NEW YORK and VIENNA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK) (“HOOKIPA” or the “Company”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform [...]
BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
30/08/2024
SUNNYVALE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced [...]
LAZCLUZE™ (lazertinib) Now Available from Onco360 for the First-line Treatment, in Combination with Rybrevant®, of Adult Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Have EGFR Exon 19 Deletions or Exon 21 L858R Mutations
30/08/2024
LOUISVILLE, Ky., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Johnson & Johnson for LAZCLUZE ™ (lazertinib). LAZCLUZE [...]

Pages